A5046070636- Inflammatory Bowel Disease
- Microscopic Colitis
- Eosinophilic Esophagitis
- Helicobacter pylori-related gastroenterology studies
- Biosimilars and Bioanalytical Methods
- Celiac Disease Research and Management
- Immunodeficiency and Autoimmune Disorders
- Genetic factors in colorectal cancer
- Autoimmune and Inflammatory Disorders
- SARS-CoV-2 and COVID-19 Research
- Vitamin D Research Studies
- Pharmaceutical studies and practices
- Diverticular Disease and Complications
- Gastric Cancer Management and Outcomes
- Colorectal Cancer Screening and Detection
- COVID-19 Clinical Research Studies
- Liver Diseases and Immunity
- Gastrointestinal disorders and treatments
- Bone Metabolism and Diseases
- Cytokine Signaling Pathways and Interactions
- Pregnancy and Medication Impact
- Pancreatitis Pathology and Treatment
- Mycobacterium research and diagnosis
- Autoimmune and Inflammatory Disorders Research
- Digestive system and related health
Semmelweis University
2016-2025
University of Szeged
2017-2023
Goethe University Frankfurt
2023
Agaplesion Markus Hospital
2023
Buda Health Center
2019
University of Debrecen
2017
Budapest University of Economics and Business
2008-2015
IRCCS San Camillo Hospital
2014
National and Kapodistrian University of Athens
2013
Aretaeio Hospital
2013
Adalimumab is a fully human monoclonal antibody targeting tumour necrosis factor with proven efficacy in the treatment of Crohn's disease (CD).To investigate predictors medium-term clinical and mucosal healing during adalimumab therapy, patients CD, specialised centres approved for biological therapy Hungary.Data capture 201 CD was standardised prospective (male/female: 112/89, median age: 33.0 years, duration: 8 years). Previous infliximab had been administered 48% patients, concomitant...
BACKGROUND Antibodies to Saccharomyces cerevisiae (S. cerevisiae) (ASCA) and porin protein-C of Escherichia coli (anti-OmpC) are associated with disease phenotype may be diagnostic importance in inflammatory bowel diseases (IBD). Our aim was determine whether a panel new antibodies against bacterial proteins carbohydrates could help differentiate among the various forms IBD, they were particular clinical manifestations Hungarian cohort IBD patients. METHODS Six hundred fifty-two...
Vitamin D is essential for osteopenia therapy in Crohn's disease (CD). The active form of vitamin-D (aVD) the 1,25(OH)2D. There are no data available whether aVD or plain (pVD) has any advantage managing osteoporosis CD effect on activity itself. Our work a prospective study to compare effects and pVD bone metabolism clinical course CD. In all, 37 inactive patients were involved divided into 2 age-, gender-, t-score-matched groups. Group A was treated with while group B received pVD....
Gene expression analysis of colon biopsies using high‐density oligonucleotide microarrays can contribute to the understanding local pathophysiological alterations and functional classification adenoma (15 samples), colorectal carcinomas (CRC) (15) inflammatory bowel diseases (IBD) (14). Total RNA was extracted, amplified biotinylated from frozen colonic biopsies. Genome‐wide gene profile evaluated by HGU133plus2 verified RT‐PCR. We applied two independent methods for data normalization used...
Background Determination of methylated Septin 9 (mSEPT9) in plasma has been shown to be a sensitive and specific biomarker for colorectal cancer (CRC). However, the relationship between DNA colon tissue same subjects not reported. Methods Plasma matching biopsy samples were collected from 24 patients with no evidence disease (NED), 26 adenoma 34 CRC. Following bisulfite conversion commercial RT-PCR assay was used determine total amount each sample fraction mSEPT9 DNA. The Septin-9 protein...
Background: The neuroendocrine marker, chromogranin A (CgA) increases during medium- or long-term proton-pump inhibitor (PPI) treatment. Aims: To analyze the effect of ultra-short-term and diverse dose PPI therapy on serum CgA gastrin levels evaluate treatment cessation. Patients Methods: Fasting were determined in newly diagnosed gastroesophageal reflux disease (GERD) patients (n = 54) treated with doses a 28-day period, PPIs for at least 6 months 42), subjects where could be stopped 11)....
Summary Background Some of the most important questions relating to use biological therapy in inflammatory bowel diseases concern duration maintenance therapy. Aim To assess disease course and frequency relapse Crohn's ( CD ) following discontinuation therapy, determine predictive factors for relapse. Methods One hundred twenty‐one patients who had achieved clinical remission 1 year whom was then discontinued participated this prospective observational study. Eighty‐seven received infliximab...
<b><i>Background:</i></b> It has been suggested that matrix metalloproteinases (MMPs) may play a role in the pathogenesis of inflammatory bowel diseases (IBD). However, impact serum MMPs and their inhibitors [tissue (TIMPs)] have scarcely investigated same experimental setting ulcerative colitis (UC) Crohn’s disease (CD) as well correlation with IBD activity. <b><i>Methods:</i></b> MMP-2, MMP-7, MMP-9, TIMP-1 TIMP-2 antigen levels were...
Antibodies directed against Saccharomyces cerevisiae (ASCA), perinuclear components of neutrophils (pANCA), and porin protein C Escherichia coli (anti-OmpC) are reported to be associated with disease phenotype may diagnostic importance in inflammatory bowel (IBD). Since limited data available from Eastern Europe, we assessed the above antibodies Hungarian IBD patients.In all, 653 well-characterized, unrelated consecutive patients (Crohn's [CD]: 558, m/f: 263/295, duration: 8.1 +/- 10.7...
Objective. There is limited data on pregnancy outcome in inflammatory bowel diseases (IBD) (Crohn's disease [CD] and ulcerative colitis [UC]) from Eastern Europe. The aim of our multicenter study was to compare the outcomes infants pregnancies before after diagnosis IBD. Patients methods. 97 women with IBD (36 CD 61 UC) 70 same (24 46 were compared. influence activity medical treatment during gestational age at birth, birth weight, health status newborns frequency childhood analyzed....
Background. Some of the most important questions relating to use biological therapy in inflammatory bowel diseases concern duration maintenance therapy. The RASH study revealed that previous and dose intensification are associated with restarting Crohn's disease. aim was assess disease course frequency relapse ulcerative colitis (UC) following discontinuation infliximab patients remission determine predictive factors for relapse. Patients methods. Fifty-one UC who had achieved clinical 1...
It has been previously shown that biosimilar infliximab CT-P13 is effective and safe in inducing remission inflammatory bowel diseases. We report here the 1-year outcomes from a prospective nationwide disease cohort. A prospective, nationwide, multicenter, observational cohort was designed to examine efficacy safety of induction maintenance treatment Crohn's (CD) ulcerative colitis (UC). Demographic data were collected harmonized monitoring strategy applied. Clinical remission, response,...
Celiac disease, Crohn disease and ulcerative colitis are inflammatory disorders of the gastrointestinal tract with some common genetic, immunological environmental factors involved in their pathogenesis. Several research shown that patients celiac have increased risk developing bowel when compared general population. The aim this study is to determine prevalence our patient cohort over a 15-year-long period.To diagnose serological tests were used, duodenal biopsy samples taken degree mucosal...
Biosimilar infliximab CT-P13 received European Medicines Agency [EMA] approval in June 2013 for all indications of the originator product. In present study, we aimed to evaluate predictors short- and medium-term clinical outcome patients treated with biosimilar at participating inflammatory bowel disease [IBD] centres Hungary. Demographic data were collected a harmonised monitoring strategy was applied. Clinical biochemical activities evaluated Weeks 14, 30, 54. Trough level [TL] anti-drug...
Perianal fistulas of Crohn's disease (CD) create a significant burden on patients' lives. However, the efficacy and safety adipose-derived mesenchymal stem cell treatment are contradicting, real-world evidence is lacking.
Bevezetés: A vérszegénység a gyulladásos bélbetegségek egyik leggyakoribb szövődménye és betegség súlyosságának mutatója. Célkitűzés: Vizsgálatunk célja az anaemia gyakoriságának, etiológiájának, prediktív tényezőinek kezelésének felmérése volt bélbetegségben szenvedő betegeket kezelő két tercier centrum betegpopulációjában. Módszer: Retrospektív, keresztmetszeti vizsgálatunkban egyéves időszakban (2022. 06. 01. – 2023. 05. 31.) Semmelweis Egyetem klinikáján megjelent betegek körében mértük...
Abstract Background Perianal fistulas of Crohn’s disease (CD) create a significant burden on patient lives. However, the efficacy and safety adipose-derived mesenchymal stem cell treatment are contradicting, real-world evidence is lacking. We aimed to examine usability darvadstrocel therapy in managing perianal CD. Methods In this retrospective multicenter study CD patients with were enrolled followed. The primary outcome was clinical remission (all treated have closed) at weeks 26 52, while...
Abstract Background Crohn’s disease (CD) complicated with intra-abdominal abscess often requires surgical intervention. Image guided percutaneous drainage (PD) can help to avoid interventions, however there is limited evidence on the optimal management after PD. Our study aimed analyze long-term outcomes of CD Methods In this multicenter, multinational retrospective trial penetrating patients simplex were enrolled and followed. Baseline was defined as day first detection abdominal abscess,...